L1295
拉米夫定
≥98% (HPLC), nRTI inhibitor, powder
别名:
2′,3′-二脱氧-3′-硫胞苷, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H11N3O3S
化学文摘社编号:
分子量:
229.26
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
拉米夫定, ≥98% (HPLC), powder
Quality Level
SMILES string
NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2
InChI key
JTEGQNOMFQHVDC-NKWVEPMBSA-N
InChI
1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
water: 10 mg/mL, clear
originator
GlaxoSmithKline
storage temp.
room temp
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
拉米夫定是一种有效的核苷类似物逆转录酶抑制剂（nRTI）。
拉米夫定是一种有效的核苷类似物逆转录酶抑制剂（nRTI）。 它是胞苷的类似物，除抑制乙型肝炎的逆转录酶外，还可抑制两种类型（1型和2型）的HIV逆转录酶。它需要磷酸化为其三磷酸形式才具有活性。3TC-三磷酸也抑制细胞DNA聚合酶。
Application
Lamivudine has been used to deplete the Hepatitis B Virus (HBV) covalently closed circular DNA (cccDNA) forms for the preparation of inverse nested PCR.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Chia-Yen Dai et al.
The Journal of antimicrobial chemotherapy, 68(10), 2332-2338 (2013-06-27)
For hepatitis B e antigen (HBeAg)-positive patients, continuing therapy (consolidation) for 6-12 months before cessation of nucleos(t)ide analogues (NAs) was recommended. This study aimed to investigate whether a longer period of lamivudine consolidation therapy leads to better outcomes and the
Raph L Hamers et al.
Journal of acquired immune deficiency syndromes (1999), 64(2), 174-182 (2013-07-31)
This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes. A multicenter prospective cohort of HIV-infected
Wai-Kay Seto et al.
Hepatology (Baltimore, Md.), 58(3), 923-931 (2013-03-08)
The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined. From 1994 to 2002, 322 Chinese CHB patients were started on lamivudine in our
Kiyoaki Ito et al.
Hepatology (Baltimore, Md.), 59(1), 89-97 (2013-07-31)
The proportion of patients who progress to chronicity following acute hepatitis B (AHB) varies widely worldwide. Moreover, the association between viral persistence after AHB and hepatitis B virus (HBV) genotypes in adults remains unclear. A nationwide multicenter study was conducted
Edward J Gane et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(3), 268-274 (2013-03-01)
Without effective prophylaxis, liver transplantation for hepatitis B virus (HBV)-related liver disease is frequently complicated by severe and rapidly progressive HBV recurrence. Combination prophylaxis with hepatitis B immune globulin (HBIG) and lamivudine (LAM) reduces long-term recurrence rates below 10%; however
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
Discover Bioactive Small Molecules for ADME/Tox
相关内容
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持